Ovid sells future ganaxolone royalties to Immedica for $7.0M cash

Ovid Therapeutics Inc.

Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.
Ovid recorded ~$566K in ganaxolone royalty revenue in 2024; deal provides non-dilutive funding.
Immedica also obtains additional ganaxolone IP rights and assumes future IP costs.
Transaction expands Immedica's control of ganaxolone; no impact on Ovid's pipeline.
Amended license expected within six months to broaden field and territory.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.